Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Sixt Aktie 348141 / DE0007231326

10.11.2025 12:00:03

EQS-News: Growth financing: SIXT SE expands syndicated loan to EUR 1.55 billion and extends maturity until at least 2030

EQS-News: Sixt SE / Key word(s): Financing
Growth financing: SIXT SE expands syndicated loan to EUR 1.55 billion and extends maturity until at least 2030

10.11.2025 / 12:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Growth financing: SIXT SE expands syndicated loan to EUR 1.55 billion and extends maturity until at least 2030

 

  • Credit line increased by a further EUR 600 million to EUR 1.55 billion.
  • Term of five years until 2030 (plus two extension options until 2032) secures growth financing.
  • Dr Franz Weinberger, CFO of Sixt SE: “The successful completion of the significantly increased syndicated loan once again proves the confidence of the banks in our company. In this way, we are expanding our financial room for manoeuvre and strengthening our already very solid liquidity situation in the long term. At the same time, we were able to achieve significantly better conditions in a challenging market environment – as the first syndicated loan since the publication of our rating.“

 

Pullach, November 10th, 2025 - Sixt SE has replaced its previous syndicated loan of EUR 950 million with a new revolving credit line of EUR 1.55 billion ahead of schedule.

Not least thanks to the rating of Sixt SE (BBB), the company was able to negotiate significantly more favorable conditions. The new syndicated loan has a term of five years and can be extended twice by one year each time – up to a maximum of 2032.

The credit line can be drawn down in various currencies, in particular euros and US dollars. It primarily serves to strengthen the already comfortable liquidity position of Sixt SE and is available to the company as an additional financing reserve. Sixt SE is thus once again expanding its financial scope and strengthening its financial flexibility to implement its growth course.

The banking consortium consists of Bayerische Landesbank, CaixaBank, Commerzbank, Deutsche Bank, DZ BANK, ING, Helaba and UniCredit Bank. The syndication was arranged by Sixt SE itself.

Dr. Franz Weinberger, CFO of Sixt SE, explains: "The successful conclusion of the significantly enlarged syndicated loan agreement demonstrates the confidence of the banks in our company. The long term underlines our financial solidity. In this way, we are expanding our financial room for manoeuvre and strengthening our already very solid liquidity situation in the long term. At the same time, we were able to achieve significantly better conditions in a challenging market environment – as the first syndicated loan since the publication of our rating."

 

About SIXT:

Sixt SE with its registered office in Pullach near Munich, is a leading international provider of high-quality mobility services. With its products SIXT rent, SIXT share, SIXT ride and SIXT+ on the mobility platform ONE the company offers a uniquely integrated premium mobility service across the fields of vehicle and commercial vehicle rental, car sharing, ride hailing and car subscriptions. The products can be booked, among others, via the SIXT App, which also integrates the services of its renowned mobility partners. SIXT has a presence in more than 100 countries around the globe. The company stands for consistent customer orientation, a lived culture of innovation with strong technological competence, a high proportion of premium vehicles in the fleet and an attractive price-performance ratio. In 2023 Sixt Group achieved consolidated pre-tax earnings of EUR 464.3 million and another significant increase in consolidated revenue to EUR 3.62 billion. Sixt SE has been listed on the Frankfurt Stock Exchange since 1986 (ISIN ordinary share: DE0007231326, ISIN preference share: DE0007231334).

 

Press contact:

Mark Christian Schneider

Phone: +49 – (0)89 – 74444 6700

Email: pressrelations@sixt.com

 



10.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Sixt SE
Zugspitzstrasse 1
82049 Pullach i. Isartal
Germany
Phone: +49 (0)89 74444-5104
Fax: +49 (0)89 74444-85104
E-mail: investorrelations@sixt.com
Internet: http://ir.sixt.eu
ISIN: DE0007231326, DE0007231334 Sixt Vorzüge, DE000A1K0656 Sixt Namensaktien, DE000A2G9HU0 Sixt-Anleihe 2018/2024, DE000A3H2UX0 Sixt-Anleihe 2020/2024
WKN: 723132
Indices: SDAX
Listed: Regulated Market in Frankfurt, Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 2226906

 
End of News EQS News Service

2226906  10.11.2025 CET/CEST

Analysen zu Sixt SE St.

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
28.10.25 Sixt Buy Jefferies & Company Inc.
17.10.25 Sixt Buy Jefferies & Company Inc.
15.10.25 Sixt Buy Warburg Research
13.10.25 Sixt Kaufen DZ BANK
03.10.25 Sixt Buy Deutsche Bank AG
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’974.31 19.37 BP9SUU
Short 13’215.46 13.98 BU9S6U
Short 13’724.19 8.85 B19SNU
SMI-Kurs: 12’465.39 10.11.2025 17:30:00
Long 11’962.62 19.84 SNLBQU
Long 11’690.01 13.82 SSTBSU
Long 11’209.46 8.98 SQZB6U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com